

SECOND AMENDMENT AFTER FINAL
U.S. Appln. No. 10/664,859

REMARKS

In the Advisory Action, the Examiner has refused to enter the Amendment After Final filed January 24, 2007, on the basis that, *inter alia*, such raises new issues which would require further consideration and/or search. Specifically, the Examiner states that Claim 61 has been amended to refer to SEQ ID Nos: 3 and 5, which the Examiner contends raise an obviousness-type double patenting issue with respect to parent patent 7,049,290.

Accordingly, Applicants submit herewith a Terminal Disclaimer obviating any such obviousness-type double patenting issue.

Applicants also note, the Examiner states that Claim 61(ii) does not overcome Venter et al.

Accordingly, Applicants hereby delete part (ii) from Claim 61.

Applicant also note that the Examiner has advised that with respect to parts (iv), (vi) and (vii), the expression "a peptide of (i)" should be amended to recite "peptide fragment of (i)".


Accordingly, Applicants hereby amend Claim 61 as suggested by the Examiner.

In view of the amendments to the claims, the Examiner is requested to pass the case to issuance.

**SECOND AMENDMENT AFTER FINAL
U.S. Appln. No. 10/664,859**

The Examiner is invited to contact the undersigned at his Washington telephone number on any questions which might arise.

Respectfully submitted,


Gordon Kit

Registration No. 30,764

SUGHRUE MION, PLLC

Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: May 10, 2007